Abstract
Background: Probiotics and antispasmodics have been tested extensively in the management of symptoms of irritable bowel syndrome (IBS), but they have rarely been evaluated in combination. The objective of this pilot study was to assess the efficacy of treatment with the probiotic formulation i3.1 (Lactobacillus plantarum CECT7484 and CECT7485 and Pediococcus acidilactici CECT7483), with or without the addition of the antispasmodic alverine/simethicone, in improving IBS-related quality of life (QoL) and reducing abdominal pain and diarrhea in patients with IBS. Methods: This was a randomized, placebo-controlled clinical trial with 3 parallel arms (probiotic, probiotic plus antispasmodic, and placebo). Patients with IBS (N = 55) were recruited at the Gastroenterology Department of the Juárez Hospital (México City). QoL was assessed with the IBS-QoL questionnaire, abdominal pain with a visual analog scale, and stool consistency with the Bristol scale. Results: The IBS-QoL rate of response (ITT analysis) was 50.0% for patients in the group with probiotic alone, 68.4% in the group with probiotic plus antispasmodic, and 16.7% in the group with placebo after 6 weeks of treatment (p = 0.005). Response to abdominal pain was reported by 38.9% of patients treated with probiotic, 57.9% with probiotic plus antispasmodic, and 16.7% with placebo (p = 0.035). Regarding stool consistency, a response to treatment was reported by 44.4% of patients treated with probiotic, 57.9% with probiotic plus antispasmodic, and 16.7% with placebo (p = 0.032). Conclusion: The results are consistent with previous studies on the use of the i3.1 probiotic formulation for the management of symptoms in IBS patients, and the addition of an antispasmodic improves its observed effects.
References
1.
Quigley
EM
, Fried
M
, Gwee
KA
, Khalif
I
, Hungin
AP
, Lindberg
G
, et al World gastroenterology organisation global guidelines irritable bowel syndrome: a global perspective update September 2015
. J Clin Gastroenterol
. 2016
;50
(9
):704
–13
. .2.
Martin
CR
, Osadchiy
V
, Kalani
A
, Mayer
EA
. The brain-gut-microbiome axis
. Cell Mol Gastroenterol Hepatol
. 2018
;6
(2
):133
–48
. .3.
Osadchiy
V
, Martin
CR
, Mayer
EA
. The gut-brain axis and the microbiome: mechanisms and clinical implications
. Clin Gastroenterol Hepatol
. 2019
;17
(2
):322
–32
. .4.
Shin
A
, Preidis
GA
, Shulman
R
, Kashyap
PC
. The gut microbiome in adult and pediatric functional gastrointestinal disorders
. Clin Gastroenterol Hepatol
. 2019
;17
(2
):256
–74
. .5.
Lovell
RM
, Ford
AC
. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis
. Clin Gastroenterol Hepatol
. 2012
;10
(7
):712
–e4
. .6.
Sperber
AD
, Dumitrascu
D
, Fukudo
S
, Gerson
C
, Ghoshal
UC
, Gwee
KA
, et al The global prevalence of IBS in adults remains elusive due to the heterogeneity of studies: a Rome Foundation working team literature review
. Gut
. 2017
;66
(6
):1075
–82
. .7.
Carmona-Sanchez
R
, Icaza-Chavez
ME
, Bielsa-Fernandez
MV
, Gomez-Escudero
O
, Bosques-Padilla
F
, Coss-Adame
E
, et al The Mexican consensus on irritable bowel syndrome
. Rev Gastroenterol Mex
. 2016
;81
:149
–67
.8.
El-Serag
HB
, Olden
K
, Bjorkman
D
. Health-related quality of life among persons with irritable bowel syndrome: a systematic review
. Aliment Pharmacol Ther
. 2002
;16
(6
):1171
–85
. .9.
Flacco
ME
, Manzoli
L
, De Giorgio
R
, Gasbarrini
A
, Cicchetti
A
, Bravi
F
, et al Costs of irritable bowel syndrome in European countries with universal healthcare coverage: a meta-analysis
. Eur Rev Med Pharmacol Sci
. 2019
;23
(7
):2986
–3000
. .10.
Coffin
B
, Dapoigny
M
, Cloarec
D
, Comet
D
, Dyard
F
. Relationship between severity of symptoms and quality of life in 858 patients with irritable bowel syndrome
. Gastroenterol Clin Biol
. 2004
;28
(1
):11
–5
. .11.
Cangemi
DJ
, Lacy
BE
. Management of irritable bowel syndrome with diarrhea: a review of nonpharmacological and pharmacological interventions
. Therap Adv Gastroenterol
. 2019
;12
:1756284819878950
. .12.
Annahazi
A
, Roka
R
, Rosztoczy
A
, Wittmann
T
. Role of antispasmodics in the treatment of irritable bowel syndrome
. World J Gastroenterol
. 2014
;20
:6031
–43
.13.
Ruepert
L
, Quartero
AO
, de Wit
NJ
, van der Heijden
GJ
, Rubin
G
, Muris
JW
. Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome
. Cochrane Database Syst Rev
. 2011
(8
):CD003460
. .14.
Coelho
AM
, Jacob
L
, Fioramonti
J
, Bueno
L
. Rectal antinociceptive properties of alverine citrate are linked to antagonism at the 5-HT1A receptor subtype
. J Pharm Pharmacol
. 2001
;53
(10
):1419
–26
. .15.
Bueno
L
, Beaufrand
C
, Theodorou
V
, Andro-Delestrain
MC
. Influence of simethicone and alverine on stress-induced alterations of colonic permeability and sensitivity in rats: beneficial effect of their association
. J Pharm Pharmacol
. 2013
;65
(4
):567
–73
. .16.
Wittmann
T
, Paradowski
L
, Ducrotté
P
, Bueno
L
, Andro Delestrain
MC
. Clinical trial: the efficacy of alverine citrate/simeticone combination on abdominal pain/discomfort in irritable bowel syndrome: a randomized, double-blind, placebo-controlled study
. Aliment Pharmacol Ther
. 2010
;31
(6
):615
–24
. .17.
Ducrotte
P
, Grimaud
JC
, Dapoigny
M
, Personnic
S
, O’Mahony
V
, Andro-Delestrain
MC
. On-demand treatment with alverine citrate/simeticone compared with standard treatments for irritable bowel syndrome: results of a randomised pragmatic study
. Int J Clin Pract
. 2014
;68
(2
):245
–54
. .18.
Vich Vila
A
, Imhann
F
, Collij
V
, Jankipersadsing
SA
, Gurry
T
, Mujagic
Z
, et al Gut microbiota composition and functional changes in inflammatory bowel disease and irritable bowel syndrome
. Sci Transl Med
. 2018
;10
(472
):eaap8914
. .19.
Chong
PP
, Chin
VK
, Looi
CY
, Wong
WF
, Madhavan
P
, Yong
VC
. The microbiome and irritable bowel syndrome: a review on the pathophysiology, current research and future therapy
. Front Microbiol
. 2019
;10
:1136
. .20.
Ford
AC
, Harris
LA
, Lacy
BE
, Quigley
EMM
, Moayyedi
P
. Systematic review with meta-analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome
. Aliment Pharmacol Ther
. 2018
;48
(10
):1044
–60
. .21.
Dale
HF
, Rasmussen
SH
, Asiller
ÖÖ
, Lied
GA
. Probiotics in irritable bowel syndrome: an up-to-date systematic review
. Nutrients
. 2019
;11
(9
):2048
. .22.
Lorenzo-Zuñiga
V
, Llop
E
, Suárez
C
, Álvarez
B
, Abreu
L
, Espadaler
J
, et al I.31, a new combination of probiotics, improves irritable bowel syndrome-related quality of life
. World J Gastroenterol
. 2014
;20
:8709
–16
.23.
World Medical Association
. Declaration of Helsinki: ethical principles for medical research involving human subjects
. JAMA
. 2013
;310
:2191
–4
.24.
Mearin
F
, Lacy
BE
, Chang
L
, Chey
WD
, Lembo
AJ
, Simren
M
, et al Bowel disorders
. Gastroenterology
. 2016
. .25.
Drossman
DA
, Patrick
DL
, Whitehead
WE
, Toner
BB
, Diamant
NE
, Hu
Y
, et al Further validation of the IBS-QOL: a disease-specific quality-of-life questionnaire
. Am J Gastroenterol
. 2000
;95
(4
):999
–1007
. .26.
Patrick
DL
, Drossman
DA
, Frederick
IO
, DiCesare
J
, Puder
KL
. Quality of life in persons with irritable bowel syndrome: development and validation of a new measure
. Dig Dis Sci
. 1998
;43
(2
):400
–11
. .27.
US Department of Health and Human Services, Food and Drug Administration (CDER)
. Irritable bowel syndrome: clinical evaluation of drugs for treatment
. Guidance for Industry
; 2012
. Available from
: https://www.fda.gov/media/78622/download Accessed 2020 Jan 22
.28.
Lewis
SJ
, Heaton
KW
. Stool form scale as a useful guide to intestinal transit time
. Scand J Gastroenterol
. 1997
;32
(9
):920
–4
. .29.
30.
Muller-Lissner
S
, Koch
G
, Talley
NJ
, Drossman
D
, Rueegg
P
, Dunger-Baldauf
C
, et al Subject’s Global Assessment of Relief: an appropriate method to assess the impact of treatment on irritable bowel syndrome-related symptoms in clinical trials
. J Clin Epidemiol
. 2003
;56
:310
–6
.31.
Loren
V
, Manye
J
, Fuentes
MC
, Cabre
E
, Ojanguren
I
, Espadaler
J
. Comparative effect of the I3.1 probiotic formula in two animal models of colitis
. Probiotics Antimicrob Proteins
. 2017
;9
:71
–80
.32.
Chen
JC
, Tsai
CC
, Hsieh
CC
, Lan
A
, Huang
CC
, Leu
SF
. Multispecies probiotics combination prevents ovalbumin-induced airway hyperreactivity in mice
. Allergol Immunopathol
. 2018 Jul–Aug
;46
(4
):354
–60
. .33.
Lim
FT
, Lim
SM
, Ramasamy
K
. Cholesterol lowering by Pediococcus acidilactici LAB4 and Lactobacillus plantarum LAB12 in adult zebrafish is associated with improved memory and involves an interplay between npc1l1 and abca1
. Food Funct
. 2017
;8
(8
):2817
–28
. .34.
Moayyedi
P
, Andrews
CN
, MacQueen
G
, Korownyk
C
, Marsiglio
M
, Graff
L
, et al Canadian association of gastroenterology clinical practice guideline for the management of irritable bowel syndrome (IBS)
. J Can Assoc Gastroenterol
. 2019
;2
(1
):6
–29
. .35.
Martinez-Vazquez
MA
, Vazquez-Elizondo
G
, Gonzalez-Gonzalez
JA
, Gutierrez-Udave
R
, Maldonado-Garza
HJ
, Bosques-Padilla
FJ
. Effect of antispasmodic agents, alone or in combination, in the treatment of irritable bowel syndrome: systematic review and meta-analysis
. Rev Gastroenterol Mex
. 2012
;77
:82
–90
.36.
Hou
X
, Chen
S
, Zhang
Y
, Sha
W
, Yu
X
, Elsawah
H
, et al Quality of life in patients with irritable bowel syndrome (IBS), assessed using the IBS-quality of Life (IBS-QOL) measure after 4 and 8 weeks of treatment with mebeverine hydrochloride or pinaverium bromide: results of an international prospective observational cohort study in Poland, Egypt, Mexico and China
. Clin Drug Investig
. 2014
;34
(11
):783
–93
. .37.
Zheng
L
, Lai
Y
, Lu
W
, Li
B
, Fan
H
, Yan
Z
, et al Pinaverium reduces symptoms of irritable bowel syndrome in a multicenter, randomized, controlled trial
. Clin Gastroenterol Hepatol
. 2015
;13
(7
):1285
–e1
. .38.
Schmulson
MJ
, Chiu-Ugalde
J
, Saez-Rios
A
, Lopez-Colombo
A
, Mateos-Perez
GJ
, Remes-Troche
JM
, et al Efficacy of the combination of pinaverium bromide 100 mg plus simethicone 300 mg in abdominal pain and bloating in irritable bowel syndrome: a randomized, placebo-controlled trial
. J Clin Gastroenterol
. 2020 Apr
;54
(4
):e30
–9
.39.
Li
B
, Liang
L
, Deng
H
, Guo
J
, Shu
H
, Zhang
L
. Efficacy and safety of probiotics in irritable bowel syndrome: a systematic review and meta-analysis
. Front Pharmacol
. 2020
;11
:332
. .© 2020 S. Karger AG, Basel
2020
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
